论文部分内容阅读
目的:评价恩替卡韦用于治疗代偿期乙型肝炎肝硬化患者血清甲状腺激素(TH)的影响。方法:选取2012年5月—2014年5月期间收治的代偿期乙型肝炎肝硬化患者104例,将其随机分为治疗组(n=52)与对照组(n=52);对照组患者给予常规综合治疗措施,治疗组患者在对照组基础上给予恩替卡韦治疗,观察两组患者治疗前后TH的变化。结果:治疗组患者治疗后T4、T3、FT3和FT4值分别为(90.23±20.45)nmol/L、(1.32±0.38)nmol/L、(6.20±2.15)pmol/L和(13.25±3.54)pmol/L,显著高于对照组分别为(65.54±18.56)nmol/L、(0.75±0.24)nmol/L、(2.65±2.22)pmol/L和(6.72±1.33)pmol/L(P<0.05);治疗前两组患者T4、T3、FT3和FT4值经比较其差异无统计学意义(P>0.05);治疗组治疗后TSH值为(2.56±1.05)m U/m L,显著低于对照组为(4.12±1.06)m U/m L(P<0.05)。结论:恩替卡韦用于代偿期乙型肝炎肝硬化患者可改善TH水平,调节肝功能代谢的紊乱状态,其疗效较为确切。
Objective: To evaluate the effect of entecavir on serum thyroid hormone (TH) in patients with decompensated hepatitis B cirrhosis. Methods: A total of 104 patients with decompensated hepatitis B cirrhosis admitted from May 2012 to May 2014 were randomly divided into treatment group (n = 52) and control group (n = 52), and control group Patients were given conventional comprehensive treatment. Patients in the treatment group were given entecavir on the basis of the control group. The changes of TH before and after treatment in both groups were observed. Results: The values of T4, T3, FT3 and FT4 in the treatment group were (90.23 ± 20.45) nmol / L, 1.32 ± 0.38 nmol / L, 6.20 ± 2.15 pmol / L and 13.25 ± 3.54 pmol respectively / L was significantly higher than that of the control group (65.54 ± 18.56 nmol / L, 0.75 ± 0.24 nmol / L, 2.65 ± 2.22 pmol / L and 6.72 ± 1.33 pmol / L, respectively ; There was no significant difference of T4, T3, FT3 and FT4 between the two groups before treatment (P> 0.05). The TSH of the treatment group was (2.56 ± 1.05) mU / m L after treatment, which was significantly lower than that of the control Group was (4.12 ± 1.06) m U / m L (P <0.05). Conclusion: The effect of entecavir on decompensated hepatitis B patients with cirrhosis can improve the level of TH, regulate the disorder of liver function and metabolism, and the curative effect is more exact.